Group 1 - The Hong Kong Innovative Drug ETF managed by Penghua (159286) experienced a decline of 0.56% on January 12, with a trading volume of 73.0144 million yuan [1] - The fund's shares decreased by 5 million, bringing the total shares to 671 million, with a reduction of 10 million shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated to be 602 million yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] - The fund has been managed by Penghua Fund Management Co., with fund managers Lin Song and Zhang Yuxiang [1] - Since its establishment on August 20, 2025, the fund has reported a return of -10.29%, while the return over the past month is 2.28% [1]

Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a decline of 1.32% on December 2, with a trading volume of 27.97 million yuan, indicating a challenging market environment for innovative drug investments [1] Group 1: Fund Performance - The latest net asset value of the Hong Kong Innovative Drug ETF is 600 million yuan [1] - Since its inception on August 20, 2025, the fund has reported a return of -9.83% [1] - Over the past month, the fund has achieved a return of 0.66% [1] Group 2: Fund Management - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang overseeing its operations [1] - The performance benchmark for the fund is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] Group 3: Fund Size and Activity - The fund's shares increased by 2 million to a total of 666 million shares, despite a reduction of 16 million shares over the last 20 trading days [1]

Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua has shown a slight increase in value, but its overall performance since inception has been negative, indicating potential challenges in the sector [1]. Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159286) increased by 0.11% on November 6, with a trading volume of 71.5588 million yuan [1]. - The fund's total shares increased by 1 million, bringing the total to 694 million shares, with a notable increase of 14.5 million shares over the last 20 trading days [1]. - The latest net asset value of the fund is 622 million yuan [1]. Group 2: Benchmark and Management - The performance benchmark for the fund is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1]. - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang [1]. - Since its establishment on August 20, 2025, the fund has recorded a return of -10.40%, and a return of -11.44% over the past month [1].

Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a decline of 2.71% on October 30, with a trading volume of 654.934 million yuan, indicating a challenging market environment for innovative drug investments [1] Group 1: Fund Performance - The fund's latest net asset value is calculated at 588 million yuan [1] - Since its inception on August 20, 2025, the fund has reported a return of -13.59% [1] - Over the past month, the fund's return has been -14.59% [1] Group 2: Fund Activity - The fund's shares increased by 11 million shares on the same day, bringing the total shares to 681 million [1] - In the last 20 trading days, the fund's shares have increased by 136 million shares [1] Group 3: Benchmark and Management - The performance benchmark for the fund is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang [1]

Group 1 - The Hong Kong Innovative Drug ETF Penghua (159286) experienced a decline of 4.01% on October 14, with a trading volume of 89.768 million yuan [1] - The fund's shares increased by 18 million to a total of 587 million shares, with a net asset value of 530 million yuan [1] - Over the past 20 trading days, the fund's shares have increased by 42 million [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF Penghua is the National Index of Hong Kong Stock Connect Innovative Drugs, adjusted for exchange rates [1] - The fund has been managed by Penghua Fund Management Co., Ltd., with managers Lin Song and Zhang Yuxiang [1] - Since its establishment on August 20, 2025, the fund has reported a return of -9.69%, with a one-month return of -10.57% [1]

Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a 2.02% increase in value on September 30, with a trading volume of 136 million yuan, despite a reduction in shares outstanding [1] Group 1: Fund Performance - The fund's latest net asset value is calculated at 555 million yuan [1] - Since its inception on August 20, 2025, the fund has returned 1.17% [1] - Over the past month, the fund has achieved a return of 3.44% [1] Group 2: Share Dynamics - On the reporting date, the fund's shares decreased by 9 million, bringing the total outstanding shares to 549 million [1] - In the last 20 trading days, the fund's shares have decreased by 11 million [1] Group 3: Benchmark and Management - The fund's performance benchmark is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang [1]

Group 1 - The core viewpoint of the article highlights the performance of the Hong Kong Innovative Drug ETF managed by Penghua, which saw a slight increase in value but a significant reduction in shares over the recent trading period [1] - On September 29, the ETF's share price increased by 0.61%, with a trading volume of 88.4433 million yuan [1] - The ETF's total shares decreased by 3 million, bringing the latest total to 558 million shares, with a reduction of 15 million shares over the past 20 trading days [1] Group 2 - The latest net asset value of the ETF is calculated to be 550 million yuan [1] - The performance benchmark for the ETF is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] - Since its inception on August 20, 2025, the ETF has recorded a return of -1.33%, while the return over the past month is 0.88% [1]